Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical Trial Landscape in NASH.
Harrison SA, Loomba R, Dubourg J, Ratziu V, Noureddin M. Harrison SA, et al. Among authors: dubourg j. Clin Gastroenterol Hepatol. 2023 Jul;21(8):2001-2014. doi: 10.1016/j.cgh.2023.03.041. Epub 2023 Apr 12. Clin Gastroenterol Hepatol. 2023. PMID: 37059159 Free article. Review.
Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1).
Harrison SA, Thang C, Bolze S, Dewitt S, Hallakou-Bozec S, Dubourg J, Bedossa P, Cusi K, Ratziu V, Grouin JM, Moller DE, Fouqueray P. Harrison SA, et al. Among authors: dubourg j. J Hepatol. 2023 May;78(5):914-925. doi: 10.1016/j.jhep.2023.02.004. Epub 2023 Feb 18. J Hepatol. 2023. PMID: 36804402 Clinical Trial.
Challenges and opportunities in NASH drug development.
Harrison SA, Allen AM, Dubourg J, Noureddin M, Alkhouri N. Harrison SA, et al. Among authors: dubourg j. Nat Med. 2023 Mar;29(3):562-573. doi: 10.1038/s41591-023-02242-6. Epub 2023 Mar 9. Nat Med. 2023. PMID: 36894650 Review.
Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study.
Fouqueray P, Bolze S, Dubourg J, Hallakou-Bozec S, Theurey P, Grouin JM, Chevalier C, Gluais-Dagorn P, Moller DE, Cusi K. Fouqueray P, et al. Among authors: dubourg j. Cell Rep Med. 2021 Dec 21;2(12):100474. doi: 10.1016/j.xcrm.2021.100474. eCollection 2021 Dec 21. Cell Rep Med. 2021. PMID: 35028615 Free PMC article. Clinical Trial.
Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period.
Reilhac C, Dubourg J, Thang C, Grouin JM, Fouqueray P, Watada H. Reilhac C, et al. Among authors: dubourg j. Diabetes Obes Metab. 2022 May;24(5):838-848. doi: 10.1111/dom.14642. Epub 2022 Feb 8. Diabetes Obes Metab. 2022. PMID: 34984815 Free PMC article. Clinical Trial.
Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study.
Cusi K, Alkhouri N, Harrison SA, Fouqueray P, Moller DE, Hallakou-Bozec S, Bolze S, Grouin JM, Jeannin Megnien S, Dubourg J, Ratziu V. Cusi K, et al. Among authors: dubourg j. Lancet Gastroenterol Hepatol. 2021 Nov;6(11):889-902. doi: 10.1016/S2468-1253(21)00300-9. Epub 2021 Sep 22. Lancet Gastroenterol Hepatol. 2021. PMID: 34560015 Clinical Trial.
38 results